CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health, today reported financial and operating results for the second quarter ended June 30, 2016.
Commenting on recent key developments, David A. Dodd, President and Chief Executive Officer of the Company, stated, “After the end of Q2, we concluded two important out-license agreements for Zoptrex™, confirming the market’s interest in our lead oncology compound, Zoptrex™ (zoptarelin doxorubicin). Zoptrex™ is a novel synthetic peptide carrier linked to doxorubicin as a New Chemical Entity (NCE).
Commenting on recent key developments, David A. Dodd, President and Chief Executive Officer of the Company, stated, “After the end of Q2, we concluded two important out-license agreements for Zoptrex™, confirming the market’s interest in our lead oncology compound, Zoptrex™ (zoptarelin doxorubicin). Zoptrex™ is a novel synthetic peptide carrier linked to doxorubicin as a New Chemical Entity (NCE).
